A carregar...
Epigenetic inhibition of adaptive bypass responses to lapatinib by targeting BET Bromodomains
The characterization of kinases as oncogenic drivers has led to more than 30 FDA-approved targeted kinase inhibitors for cancer treatment. Unfortunately, these therapeutics fail to have clinical durability because of adaptive responses from the kinome and transcriptome that bypass inhibition of the...
Na minha lista:
| Publicado no: | Mol Cell Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4845204/ https://ncbi.nlm.nih.gov/pubmed/27308566 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/23723556.2015.1052182 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|